<--- Back to Details
First PageDocument Content
Blood / Coagulation system / Haemophilia / Medicine / Peripheral membrane proteins / CSL Behring / Recombinant proteins / CSL Limited / Factor VII / Haemophilia B / Von Willebrand disease / Coagulation
Date: 2013-11-18 05:52:29
Blood
Coagulation system
Haemophilia
Medicine
Peripheral membrane proteins
CSL Behring
Recombinant proteins
CSL Limited
Factor VII
Haemophilia B
Von Willebrand disease
Coagulation

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

Add to Reading List

Source URL: www.cslbehring.at

Download Document from Source Website

File Size: 82,87 KB

Share Document on Facebook

Similar Documents

News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1qHpD - View Document

News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1q38M - View Document

News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1pMmB - View Document

13307 FT Factor VII plasma deficient

13307 FT Factor VII plasma deficient

DocID: 1mVEV - View Document

UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows  Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •

UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •

DocID: 1kAcN - View Document